Rapamycin / sirolimus protocols
Rapamycin (sirolimus) inhibits mTOR, a master regulator of cellular growth and autophagy, and has reproducibly extended lifespan in model organisms including a landmark 2009 NIA mouse study. It is FDA-approved for transplant rejection but used off-label at lower doses by a small number of longevity physicians. Human trials, including the PEARL trial, are underway but have not yet produced definitive efficacy or long-term safety data in healthy adults. No major medical body endorses it for longevity use. No Atlas clinic currently offers it explicitly. Evidence tier: experimental.
What it is
Rapamycin (generic name: sirolimus) is an FDA-approved macrolide compound originally developed as an immunosuppressant for organ transplant rejection prevention, now being repurposed in the longevity field for its inhibitory action on mTOR, the mechanistic target of rapamycin. mTOR is a central cellular signaling node that integrates nutrient availability, energy status, and growth-factor signals to regulate cellular growth, protein synthesis, autophagy, and a range of aging-associated processes. At the transplant doses used clinically, rapamycin produces significant immunosuppression; the longevity hypothesis is that substantially lower intermittent doses may shift cellular behavior toward autophagy and away from anabolic excess without clinically significant immune compromise. The evidence foundation at the organismal level is robust for model organisms: rapamycin produced the first demonstrated lifespan extension in middle-aged mice through the National Institute on Aging's Interventions Testing Program, published in Nature in 2009, and has since been replicated in multiple species. What remains genuinely unestablished is whether these findings translate to meaningful lifespan or healthspan extension in humans at the doses being used off-label, and what the long-term risk profile looks like in healthy adults taking it for longevity rather than transplant indications. Human trials are underway but have not yet produced definitive efficacy data. Off-label prescribing is active but limited to a small number of physicians. Rapamycin is not endorsed by any major medical body for longevity use, and the field itself acknowledges that this remains an area of active investigation rather than settled clinical practice.
Who it is for
The current clinical population receiving off-label rapamycin for longevity purposes consists almost entirely of adults who actively sought it out from the small number of physicians willing to prescribe it off-label, typically biologically sophisticated individuals with high health engagement and access to longevity medicine networks. There is no established clinical profile for who should or should not receive it outside of transplant indications. Human trial enrollment criteria vary by study. The modality carries meaningful uncertainty regarding both benefit and harm in healthy adults, which limits characterization of a benefiting population beyond trial participants.
What to expect
Off-label rapamycin for longevity is typically prescribed as a weekly oral dose, commonly ranging from 5 to 10 mg, taken intermittently rather than daily, on the theory that intermittent dosing achieves mTOR inhibition with reduced impact on immune function compared to continuous transplant dosing. Alan Green MD, who has published observational data on a patient cohort taking low-dose rapamycin, represents the most documented off-label practice in the public literature. Prescribing physicians typically conduct baseline bloodwork including metabolic panel, lipid panel, CBC, and inflammatory markers, and monitor for known adverse effects including elevated triglycerides, mouth sores (aphthous ulcers), and potential immunosuppression. Patients are counseled about the off-label nature of use and the absence of long-term human safety data at longevity doses. This is not a clinic-delivered intervention in the conventional sense. It is a prescription drug taken at home under physician monitoring.
History and background
Rapamycin was first isolated in 1972 from soil bacteria (Streptomyces hygroscopicus) discovered on Easter Island, Rapa Nui, from which it takes its name. It was developed as an antifungal and subsequently found to have potent immunosuppressive and anti-proliferative properties, leading to FDA approval in 1999 for kidney transplant rejection prevention. The 2009 NIA Interventions Testing Program publication in Nature, demonstrating lifespan extension in genetically heterogeneous mice even when treatment began at an age equivalent to roughly 60 in human years, generated substantial scientific interest in rapamycin's aging biology. The discovery and characterization of mTOR as a pathway, and its connection to nutrient sensing, autophagy, and longevity across species, preceded this finding and provided the mechanistic framework. David Sabatini's laboratory work on mTOR complex biology through the 2000s was foundational to the field's mechanistic understanding.
Worth knowing
The 2009 ITP mouse study was notable not only for extending lifespan but for doing so when treatment was initiated at a mouse age equivalent to roughly 60 human years, suggesting that mTOR inhibition can still produce lifespan effects even when initiated in mid-to-late life rather than early life. This is a meaningful finding for a longevity therapeutic, as most interventions work better when started earlier. Rapamycin's immunosuppressive mechanism at transplant doses, inhibiting T-cell proliferation, is what makes it clinically effective in organ rejection, but lower-dose longevity protocols operate on the assumption that the autophagy-promoting effects at reduced doses can be separated from the immunosuppression, an assumption that is plausible but not definitively established in humans. mTOR, the protein rapamycin inhibits, is the same pathway activated by the resistance training and dietary protein that longevity medicine recommends in other contexts, illustrating that the pathway's role in aging is highly context-dependent.
Related modalities